论文部分内容阅读
目的肿瘤标志物癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白(CYFRA21-1)联合检测对良、恶性胸腔积液的鉴别诊断意义。方法应用罗氏化学发光免疫分析系统分别检测良、恶性胸腔积液患者的血清和胸腔积液CEA、NSE、CYFRA21-1水平。结果恶性积液组血清和胸腔积液CEA、NSE、CYFRA21-1水平明显高于良性胸腔积液组,3种肿瘤标志物联合检测的灵敏度和准确度分别为91.49%和88.17%。均优于单项检测。结论肿瘤标志物联检可提高恶性积液检测的灵敏度和准确度,对良、恶性积液的鉴别诊断有意义。
Objective To evaluate the differential diagnosis of benign and malignant pleural effusion by combining the detection of carcinoembryonic antigen (CEA), neuron specific enolase (NSE) and cytokeratin (CYFRA21-1). Methods The serum and pleural effusion CEA, NSE and CYFRA21-1 levels in benign and malignant pleural effusion were detected by Roche chemiluminescence immunoassay system. Results The serum levels of CEA, NSE and CYFRA21-1 in malignant effusion group were significantly higher than those in benign pleural effusion group. The sensitivity and accuracy of the combined detection of the three tumor markers were 91.49% and 88.17% respectively. All better than single test. Conclusions The joint detection of tumor markers can improve the sensitivity and accuracy of detection of malignant effusion and is of significance for the differential diagnosis of benign and malignant effusion.